Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
Webcast Scheduled for Thursday, January 2 at 4:30 p.m. Eastern
網絡直播定於東部時間1月2日星期四下午4:30舉行
CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the second quarter of fiscal year 2025 on Thursday, January 2, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore's senior management team will host a webcast to discuss financial results for the quarter and review recent corporate developments.
明尼蘇達州查斯卡，2024年12月19日（全球新聞稿）——Lifecore生物醫藥公司（納斯達克：LFCR）（「Lifecore」），一家完全整合的合同開發和製造組織（「CDMO」），今天宣佈將於2025年1月2日星期四市場收盤後公佈2025財年第二季度的財務業績。在當天東部時間下午4:30，Lifecore的高管團隊成員將舉行網絡直播，討論季度財務業績並回顧最近的公司動態。
To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore's website at: . Following the live webcast, a replay will be available on the company's website for at least 14 days.
要收聽現場直播，或訪問歸檔的網絡直播，請訪問Lifecore網站的投資者活動和演示頁面：. 在線直播結束後，公司網站將至少提供14天的重播。
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore's website at .
關於生活核心生物醫藥
Lifecore Biomedical, Inc.（納斯達克：LFCR）是一家完全一體化的合同開發和製造組織（CDMO），提供在開發、填充和封閉無菌注射藥物產品方面的高度差異化能力，包括複雜製劑。作爲優質注射級透明質酸的領先製造商，Lifecore擁有超過40年的專業知識，致力於成爲全球和新興生物製藥及生物技術公司的合作伙伴，幫助他們將創新推向市場。欲了解更多有關公司的信息，請訪問Lifecore的網站。
CONTACT: Lifecore Biomedical, Inc. Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
415-675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com
聯繫人：生物醫藥公司Lifecore Biomedical, Inc. 聯繫信息：
Vida戰略合作伙伴
斯蒂芬妮·迪亞斯（投資者）
415-675-7401
sdiaz@vidasp.com
TIM Brons (媒體)
415-675-7402
tbrons@vidasp.com
賴安·D·萊克 (首席財務官)
Lifecore生物醫藥
952-368-6244
ryan.lake@lifecore.com
譯文內容由第三人軟體翻譯。
